ABSTRACT Fibrinogen binding to receptors on stimulated platelets is a prerequisite for platelet aggregation. To gain further insight into the role of fibrinogen in platelet aggregation and to identify the platelet fibrinogen receptor, we developed a monoclonal anti-platelet antibody that inhibited platelet aggregation. The purified antibody, designated A2A9, inhibited platelet aggregation stimulated by 10 ,uM ADP, 10 gM epinephrine, and thrombin at 1 unit/ml without inhibiting platelet shape change or platelet secretion. A2A9 was also a competitive inhibitor of fibrinogen binding to ADP-stimulated platelets. Fifty percent inhibition of fibrinogen binding occurred at 65 nM A2A9. Direct binding studies using radiolabeled A2A& demonstrated 47,000 A2A9 binding sites on unstimulated platelets, with a dissociation constant of 60 nM. Platelets from two individuals with Glanzmann thrombasthenia bound essentially no A2A9. Therefore, these data support the hypothesis that receptor-bound fibrinogen mediates platelet aggregation. In order to identify the platelet fibrinogen receptor, A2A9 immobilized on agarose was used for affinity chromatography. Two platelet polypeptides with Mr = 140,000 and 93,000 were recovered from the immobilized A2A&. After disulfide reduction, these
Mr values were altered to 125,000 and 116,000. The smaller polypeptide was also found to contain the pIAl antigen. These data localize the epitope recognized by A2A9 to the platelet membrane glycoprotein Ub-Ia complex and suggest that this complex forms the physiologic platelet fibrinogen receptor.
Fibrinogen binding to receptors on the surface of stimulated platelets is a prerequisite for platelet aggregation (1) (2) (3) . Although these receptors have not been conclusively identified, recent work suggests that they are composed of the platelet membrane glycoproteins IIb and IIIa. For example, thrombasthenic platelets lacking glycoproteins Ilb and IIIa fail to bind fibrinogen after stimulation by ADP (1) . In addition, glycoproteins IIb and lIIa, isolated as a complex from intact platelets, specifically bind to fibrinogen adsorbed to plastic plates (4) . Finally, we have demonstrated that fibrinogen modified with the heterobifunctional reagent methyl 4-azidobenzoimidate is specifically crosslinked to glycoprotein IIIa on ADP-stimulated platelets (5) .
The development of monoclonal antibodies has facilitated the study of specific cell surface structures (6) . In order to better understand the role of receptor-bound fibrinogen in platelet aggregation and to identify the fibrinogen receptor, we developed a monoclonal anti-platelet antibody selected for its ability to inhibit platelet aggregation. This antibody was found to competitively inhibit fibrinogen binding to ADP-stimulated platelets and to be directed against the glycoprotein IIb-IIIa complex. Thus, our studies provide further evidence that receptorbound fibrinogen mediates platelet aggregation and that the platelet membrane glycoprotein IIb-IIIa complex is the physiologic platelet fibrinogen receptor.
MATERIALS AND METHODS
Production of Monoclonal Antiplatelet Antibodies. C57BL/ 6 mice from The Jackson Laboratory were immunized on three occasions with 108 washed normal human platelets. Five weeks after the initial immunization, splenic lymphocytes from these mice were fused with the mouse myeloma cell line Sp 2/0-Ag14 (7) . Fused cells were selected by culture in hypoxanthine/aminopterin/thymidine medium (8) and culture supernatants were assayed for antiplatelet activity at 10-14 days.
A radioimmunoassay was used to assay for anti-platelet antibody activity. Briefly, either 5 x 107 washed normal platelets or 5 x 105 human lymphocytes were fixed to wells of polyvinylchloride microtiter trays (Dynatech, Alexandria, VA) by using 0.001% poly(L-lysine). Sequential additions of 100 A1d of 1% bovine serum albumin and 50-100 Al of culture supernatant were then made. After incubation for 1 hr at 40C, the wells were washed and "2I-labeled rabbit anti-murine F(ab')2 (a gift from Michael Cancro) was added. After a second incubation for 1 hr at 40C, the plates were thoroughly washed, the wells were swabbed with cotton-tipped applicators to remove the adherent platelets or lymphocytes, and the "I on the applicators was measured. Those cultures whose supernatants reacted with platelets and not lymphocytes were cloned by limiting dilution. Monoclonal antibody of particular interest was produced in quantity in mouse ascitic fluid.
Purification of Monoclonal Anti-Platelet IgG. Antibody was precipitated from the ascitic fluid with 50% saturated ammonium sulfate. The precipitate was dissolved in a minimal volume of 0.125 M sodium borate buffer, pH 8.4, containing 0.075 M NaCl, dialyzed extensively against this buffer, and subjected to affinity chromatography on staphylococcal protein A-Sepharose (Pharmacia) (9) . Fractions containing anti-platelet antibody activity were eluted from the column with 0.1 M sodium citrate buffer, pH 4.5, and were immediately neutralized with 1 M Tris-HCl, pH 8.5. Antibody activity was shown to be due to an IgG2a designated A2A9.
Measurement of Platelet Function. Platelet aggregation in response to ADP, epinephrine, and thrombin was measured in a Chronolog aggregometer at 37°C (10) . For studies using gelfiltered platelets, platelet-rich plasma was gel-filtered on Sepharose 2B as described by Tangen et al. (11) . The elution buffer was Tyrode's buffer (0.14 M NaCl/0.0027 M KC1/0.012 M NaHCO3/0.0004 M NaHPO4, pH 7.4) containing human albumin at 3.5 mg/ml and 5.5 mM glucose. Agonist-stimulated platelet secretion was measured as the release of ['4C]serotonin (12) . Platelets were prelabeled with [14C]serotonin in plasma. Imipramine (1 AM) was added to the platelet suspensions prior to platelet stimulation to inhibit [14C]serotonin reuptake (13) . 2417 The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
The platelet response to ristocetin was evaluated by adding various concentrations of ristocetin (Bio/Data, Horsham, PA) dissolved in water to platelet-rich plasma in an aggregometer cuvette (14) . EDTA (4 mM) was added to the cuvette to differentiate between platelet agglutination due to ristocetin and platelet aggregation (15) .
Monoclonal Anti-Platelet Antibody Binding to Human Platelets. Purified A2A9 was radioiodinated by using chloramine-T (16). Aliquots of radiolabeled A2A9 were incubated with approximately 5 x 107 gel-filtered platelets for various time intervals at 37TC. To terminate the incubation, the platelets were sedimented through a mixture of silicone oils [Hi-phenyl silicone-DC550 and methyl silicone oil-DC200, 4:1 (vol/vol), William F. Nye, Fairhaven, MA] in an Eppendorf centrifuge (Brinkmann). The buffer and oil were aspirated and the tip of the centrifuge tube containing the pelleted platelets was sliced off and 125I was measured. The trapped space in the platelet pellet was measured independently by using the radioiodinated nonimmune mouse myeloma protein P3/X63-Ag8 (a gift from M. Cancro); it amounted to 0.15% of the initial added radioactivity. This value was subtracted from the total radioactivity in the platelet pellet to determine specific A2A9 binding. Platelets from patients with Glanzmann thrombasthenia were kindly made available to us by Margaret Johnson (Wilmington Medical Center, Wilmington, DE). Statistical analyses for these studies were performed with a Texas Instruments TI programmable 58 calculator. Fibrinogen Binding to ADP-Stimulated Human Platelets. Our fibrinogen binding assay has been described in detail (1) . Briefly, purified human fibrinogen was radiolabeled with 1251 by the iodine monochloride technique (17) . Suspensions of gelfiltered human platelets (108 per ml) were mixed with I251-labeled fibrinogen ("25I-fibrinogen) at 200 jig/ml and 0.5 mM CaCl2. To initiate fibrinogen binding, 10 ,uM ADP was added and the suspensions were incubated at 37°C for 3 min without stirring. To terminate the incubations and to separate free from platelet-bound "25I-fibrinogen, the platelets were sedimented through silicone oil. Nonspecific fibrinogen binding was determined by performing the incubations in the presence of a 10-fold excess of unlabeled fibrinogen. The effect of A2Ag on ADP-stimulated fibrinogen binding was measured by incubating unstimulated platelets with various concentrations of antibody for 2 min before performing the fibrinogen binding assay.
Isolation of Platelet Antigens by Affinity Chromatography. Affinity chromatography was performed as described by McEver et al. (18) . Purified A2A9 or nonimmune mouse IgG was coupled to cyanogen bromide-activated Sepharose 4B (1-2 mg of protein per ml of Sepharose). Human platelets, obtained from 250 ml of citrate-anticoagulated blood, were washed free of plasma protein in a buffer containing 150 mM sodium chloride, 14 mM citrate, and 0.7 mM glucose (pH 6.5), and were surface labeled with 125I by the lactoperoxidase technique (19) . The platelets were then solubilized in 1% Triton X-100 and the mixture was centrifuged at 250,000 x g to remove undissolved debris. The supernatant from this centrifugation was passed over a 10-ml column of uncoupled Sepharose 4B to remove material that nonspecifically adsorbs to Sepharose. The flow-through fraction was then applied to a 3-ml column of antibody-Sepharose. Platelet protein specifically bound to the immobilized antibody was eluted with a buffer containing 0.05 M diethylamine (pH 11.5) and 1% Triton X-100. The eluate was immediately neutralized with 2 M Tris/1% Triton, pH 7.4, and was extensively dialyzed against 0.15 M sodium chloride/0.01 M Tris HCl, pH 6.8. To remove any remaining Triton X-100, the eluted proteins were precipitated with 6 vol of cold acetone. The precipitate was dissolved in 0.01 M Tris HCl, pH 6.8, containing 3% NaDodSO4 and 10% (vol/vol) glycerol by heating at 1000C for 5 min prior to NaDodSO4/polyacrylamide slab gel electrophoresis. Disulfides were reduced with 0.2 M dithiothreitol. Electrophoresis was performed according to the method of Laemmli (20) .
To further characterize the polypeptides obtained by affinity chromatography, they were electrophoretically transferred from the slab gels to strips of nitrocellulose paper (21) . After the strips had been soaked in 0.17 M sodium borate buffer, pH 8.1, containing 0.15 M CaCl2, 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 1.5% bovine serum albumin, 0.04% sodium azide, and 0.1% Nonidet P-40, they were incubated with anti-PlAL antisera and "25I-labeled protein A (5). The strips were then extensively washed, dried, and exposed to Kodak X-Omat AR photographic film for 12-72 hr.
RESULTS
Effect of A2A9 on Human Platelet Function. To examine the effect of purified A2A9 on human platelet function, suspensions of gel-filtered human platelets containing fibrinogen at 100 Ag/ ml and 1 mM MgCl2 were incubated with various concentra- Ag/ml and 1 mM MgCl2 were incubated with various concentrations of A2Aq for 2 min at 370C. Platelet aggregation was then stimulated with 10 uM ADP, 10 ,uM epinephrine (EPI), or thrombin at 1 international unit/ml. Aggregation studies were performed at 370C in a conventional aggregometer by the method of Born (10) 2419 Effect of A2Aq on '25I-Fibrinogen Binding by ADP-Stimulated Platelets. To examine the effect of A2A9 on fibrinogen binding to ADP-stimulated platelets, suspensions of gel-filtered platelets were incubated with various concentrations of A2Aq at 37TC for 2 min. "I-Labeled fibrinogen, 0.5 mM CaCl2, and 10 ILM ADP were then added to the suspensions. After an additional 3-min incubation at 370C, the fibrinogen bound to the platelets was measured. As seen in Fig. 2 , increasing concentrations of A2A9 progressively inhibited "2I-fibrinogen binding by ADP-stimulated platelets. At "2I-fibrinogen concentrations of 100-180 Ag/ml, 50% inhibition of fibrinogen binding was produced by 10 Ag/ml (65 nM) A2Aq, whereas A2A9 at 50 tug/ ml reduced specific fibrinogen binding to 12.5 ± 2.6% (SEM) of control values.
To further characterize the inhibition of fibrinogen binding by A2A9, platelets were preincubated with A2A9 at a single concentration. Fibrinogen binding was then measured as a function of "2I-fibrinogen concentration. Examination of the binding data by using double-reciprocal plots (Fig. 3) reveals that A2A9 is a competitive inhibitor of fibrinogen binding. This suggests that the antigen recognized by A2A9 is in close proximity to the platelet fibrinogen binding site.
A2A9 Binding to Human Platelets. To measure the binding of A2Aq itself to gel-filtered platelets, platelet suspensions were incubated with various concentrations of 'NI-labeled A2A9 for 2 min at 37°C. Specific A2Aq binding was calculated after sedimenting the platelets through silicone oil. As seen in Fig. 4 , A2A9 binds to a limited number of sites on the platelet surface. Further analysis of the binding data by using Scatchard plots (23) reveals that A2A9 binds to a single class of sites (Fig. 5) . Repetition of these binding studies using platelets from 10 normal individuals demonstrates 47,000 ± 1,850 (SEM) A2A9 binding sites per platelet with a dissociation constant of 60.0 ± 7.7 nM. Binding studies were also performed with platelets from two individuals with Glanzmann thrombasthenia (Fig. 4) 1% Triton X-100 and were applied to an A2A9-Sepharose column. Antigen retained by the column was examined by NaDodSO4/polyacrylamide gel electrophoresis (Fig. 6 ). Two polypeptides with apparent Mr values of 140,000 and 93,000 were retained by the column (Fig. 6, lane C) . A faint band with an apparent Mr of 155,000 was also seen and likely represents A2A9 that bled from the column during the elution. After reduction, the apparent Mr values of the retained polypeptides were altered to 125,000 and 116,000 (Fig. 6, lane B) . Faint Fig. 4 were reanalyzed by the method of Scatchard (23) . The line represents a linear regression by least squares of the data points.
having apparent Mr values of 58,000 and 22,000 were also present and likely represent the heavy and light chains of IgG. To confirm the specificity of the A2A9-Sepharose, the eluted polypeptides were passed over a column containing the nonimmune mouse myeloma protein P3/X63-Ag8. Neither of the polypeptides retained by A2A9-Sepharose interacted with P3/X63-Ag8.
The apparent molecular weights of the polypeptides retained by A2A9-Sepharose and the alteration in molecular weight after -.
FIG. 6. Slab gel electrophoresis of platelet polypeptides isolated by
affinity chromatography on immobilized A2Aq. Washed human platelets dissolved in 1% Triton X-100 were applied to an A2A9-Sepharose column. The material eluted from the column with 0.05 M diethylamine, pH 11.5, was examined by 0.1% NaDodSO4/7.5% polyacrylamide slab gel electrophoresis. Proteins were visualized with 0.1% Coomassie blue. Lane A, Triton-solubilized platelets before application to the A2A9-Sepharose column. Lane B, eluted polypeptides after reduction with 0.2 M dithiothreitol. Lane C, eluted polypeptides unreduced. Lane D, the polypeptides seen in lane C were electrophoretically transferred to strips of nitrocellulose paper. The paper strips were then incubatedwith antiserum to the p1A' antigen followed by an incubation with 125I-labeled protein A. Lane D is an autoradiogram of the nitrocellulose paper.
reduction suggests that they are the platelet membrane glycoproteins Ilb and IIIa (18, 25, 26) . These glycoproteins are thought to form a calcium-dependent complex in the platelet membrane (27) . To (25) . A more likely explanation for our results is that the Ilb-IIIa complex was not disrupted by our experimental manipulations (27) . Thus, if A2A9 were directed against an epitope on either polypeptide or against an epitope that requires the intact complex for its expression we would expect to recover both polypeptides from the affinity column. Moreover, our result is similar to that of McEver and co-workers, who produced a monoclonal antiplatelet antibody designated Tab (18) . This antibody bound to 39,400 sites on normal platelets, bound minimally to thrombasthenic platelets, but, unlike A2Aq, had no effect on platelet function. When Tab was used for affinity chromatography, two polypeptides were recovered with molecular weights identical to those we isolated with A2Aq.
Although the number of platelet fibrinogen receptors and the number of platelet A2A9 binding sites are similar, it is still conceivable that the polypeptides recovered from A2A9 Sepharose do not contain the physiologically relevant fibrinogen binding sites. For example, A2A9 could sterically prevent fibrinogen binding to sites nearby but unrelated to Ilb-IIIa.
Against this possibility is the failure of A2A9 to bind to thrombasthenic platelets. Thrombasthenic platelets are incapable of aggregation, but when appropriately stimulated they change shape and secrete normally (22) . Thrombasthenic platelets also fail to bind fibrinogen after stimulation (1) and are deficient in the membrane glycoproteins Ilb and IIIa (34) . Normal platelets incubated with saturating concentrations of A2Aq mimic the behavior of thrombasthenic platelets. Therefore, because steric hindrance of fibrinogen binding is not a consideration with thrombasthenic platelets, it would seem unlikely that sites other than those on Ilb-IIIa function as physiologic fibrinogen receptors.
